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The rationale to treat lymphomas with immunotherapy comes from long-standing 
evidence on their distinctive immune responsiveness. Indolent B-cell non-Hodgkin 
lymphomas, in particular, establish key interactions with the immune microenvironment 
to ensure prosurvival signals and prevent antitumor immune activation. However, 
reports of spontaneous regressions indicate that, under certain circumstances, patients 
develop therapeutic antitumor immunity. Several immunotherapeutic approaches have 
been thus developed to boost these effects in all patients. To date, targeting CD20 
on malignant B cells with the antibody rituximab has been the most clinically effective 
strategy. However, relapse and resistance prevent to cure approximately half of B-NHL 
patients, underscoring the need of more effective therapies. The recognition of B-cell 
receptor variable regions as B-NHL unique antigens promoted the development of 
specific vaccines to immunize patients against their own tumor. Despite initial promising 
results, this strategy has not yet demonstrated a sufficient clinical benefit to reach the 
regulatory approval. Several novel agents are now available to stimulate immune effector 
functions or counteract immunosuppressive mechanisms, such as engineered antitumor 
T cells, co-stimulatory receptor agonist, and immune checkpoint-blocking antibodies. 
Thus, multiple elements can now be exploited in more effective combinations to break 
the barriers for the induction of anti-lymphoma immunity.
Keywords: B-cell lymphoma, immunotherapy, anticancer vaccines, tumor-associated antigens, dendritic cells, 
adaptive immune response
introduction
Lymphomas are a clinically and biologically heterogeneous group of malignancies that arise from 
mature T- or B-lymphocytes in secondary lymphoid organs. Hodgkin’s lymphomas (HLs) account 
for ~10% of all lymphomas and comprise two major disease categories based on their clinical and 
histological characteristics: classical HLs, which represent the majority of the cases, and nodular 
lymphocyte predominant HLs. Non-Hodgkin lymphomas (NHLs) instead are much more frequent 
diseases, representing the fifth most common cancer in the United States. Their incidence has pro-
gressively increased in the past three decades for non-completely certain reasons (1). About 85% of 
NHLs are of B-cell origin (B-NHLs) and includes a wide spectrum of malignancies with different 
clinical and biological courses, ranging from indolent [such as chronic lymphocytic leukemia/small 
lymphocytic lymphoma (CLL), follicular lymphoma (FL), and marginal-zone lymphoma (MZL)] to 
aggressive [such as diffuse large B-cell lymphoma (DLBCL), Burkitt’s lymphoma (BL), and mantle 
cell lymphoma (MCL)].
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These tumors, in particular the aggressive forms, are highly 
sensitive to both chemotherapy and radiotherapy (2); however, 
relapse and resistance prevent the ultimate goal of achieving 
a cure in all patients. In the last few decades, the introduction 
of improved chemotherapy regimens, monoclonal antibod-
ies (mAbs), radioimmunotherapy, and targeted therapies 
against pro-lymphoma pathways have provided significant 
advances in the management of these patients, in particular 
those with B-NHLs. The chimeric anti-CD20 mAb rituximab 
has been the most valuable addition to the B-NHL treatment 
armamentarium. Its combination with poly-chemotherapy 
still represents the standard therapy for both indolent and 
aggressive B-cell lymphomas (3, 4). However, difficulties in 
the management of relapse and resistance to rituximab (5, 6) 
and the late toxicities associated with its administration (7) 
still pose significant challenges. Alternative approaches are 
thus continuously sought to ameliorate the management and 
the clinical outcome of the many patients that become resistant 
to rituximab.
In the past 20  years, the understanding of the molecular 
basis of B-cell lymphomagenesis and the role of the lymphoma 
microenvironment has significantly progressed, thus underscor-
ing multiple novel rational therapeutic modalities for B-cell 
malignancies.
B-cell maturation is dictated by a series of steps that drive the 
development of a functional B-cell receptor (BCR) with the same 
antigen specificity as the secreted Abs that B cells will eventually 
produce. A BCR is composed of two clonally variable antigen-
binding chains (heavy and light chains) codified by several differ-
ent gene segments (V, variable; D, diversity; J, joining; C, constant), 
which need to be properly rearranged to produce a functional 
antigen-binding receptor. This occurs via an error-prone process 
involving the combinatorial rearrangement of the V, D, and J 
gene segments in the heavy (H) chain locus and the V and J gene 
segments in the light (L) chain loci. Mature (naïve) B cells carry 
a BCR composed of two identical heavy chain and two identical 
light-chain immunoglobulin (Ig) polypeptides covalently linked 
(8). Antigen recognition by naïve B cells favors their recruitment 
into lymphoid follicles where they undergo somatic hypermuta-
tion of V genes, to increase the affinity for the targeted antigenic 
epitopes, and class switch recombination at the IgH locus, for the 
production of different classes of Ab (from IgM to IgG, IgA, or 
IgE). These processes form the germinal center (GC) reactions, 
whereby new B-cell clones expressing Abs with improved antigen 
specificity and suitable class are positively selected by receiving 
the proper survival signals from follicular dendritic cells (DCs) 
presenting the pathogenic antigens and helper T cells (9). If, on 
one hand, these events are required to increase the probability 
of generating a specific B-cell response able to clear infecting 
pathogens, on the other, they pose at risk of developing oncogenic 
mutations. DNA rearrangement, induction of somatic mutation, 
and provision of anti-apoptotic/pro-survival signals from the 
microenvironment during the B-cell maturation process may 
all favor the generation of a malignant B-cell clone if not tightly 
regulated. Reciprocal chromosomal translocations involving 
one of the Ig loci and a proto-oncogene, which may occur as 
by-products of the extensive DNA rearrangement during the GC 
reactions, constitute the hallmarks, and thus diagnostic markers, 
of many types of B-cell lymphoma (10, 11) (Table 1).
Mutations in pro-apoptotic genes (CD95), tumor-suppressor 
genes (TP53, PTEN), BCR downstream signaling pathways 
(CD79B/A, IκBα, CARD11, API2–MALT1 translocation) and 
other oncogenes (EZH2, Jak2, genomic amplifications REL) are 
associated to specific subtypes of B-cell lymphomas, indicating a 
role of these events in their pathogenesis (Table 1).
Finally, viruses may also be involved in lymphoma transfor-
mation, in particular Epstein–Barr virus (EBV), Kaposi’s sarcoma 
herpesvirus (KSHV), human immunodeficiency virus type 1 
(HIV-1), and human hepatitis C virus (HCV). They can directly 
infect and transform B or T cells (EBV and KSHV), or induce 
lymphocyte transformation as a consequence of chronic inflam-
mation (HIV, EBV, and hepatitis viruses), or, more indirectly, 
promote the onset of neoplastic clones by causing immunodefi-
ciency (HIV-1) (12). The most obvious example in this regard is 
EBV, which is found in nearly all the endemic BLs and in many 
post-transplant and primary effusion lymphomas (13, 14).
The possibility to interfere with ongenic pathways activated 
in the different subtypes of B-cell lymphomas has been an 
area of intense investigation, with two molecular inhibitors 
targeting bruton tyrosine kinase (ibrutininb) (15–17) or PI3K 
(idelalisib) (18) receiving the FDA approval for the treatment 
of relapsed/resistant B-NHLs in the last 2 years. However, since 
these therapies target oncogenic events associated to specific 
molecular lymphoma subtypes, they are unlikely to be available 
for all rituximab-resistant patients, and imply the requirement 
of an up-front extensive molecular characterization. In addition, 
being directed against a single molecular target, these drugs may 
induce the selection of resistant clones. This indicates the need 
to integrate anti-lymphoma treatments in multicombinatorial 
therapeutic approaches, which employ different strategies to 
reach the desired improvement in clinical benefit.
Immunotherapy seems one of the best candidates because of 
the easy accessibility of lymphomas by the immune system as they 
grow in secondary lymphoid organs and the availability of unique 
targetable tumor-specific antigens. The major advantage of 
immunotherapy is the possibility to induce an adaptive immune 
response against the tumor, with the potential to generate a long-
lasting immunological memory able to prevent further relapses. 
Carrying the same BCR on the surface, B-cell lymphomas are 
distinguished by the unique antigenic determinants of BCR 
hypervariable regions, termed idiotype (Id), which constitutes 
a prototype immunotherapeutic target to specifically redirect 
immune responses against the malignant clone. The clonotypic 
Id of B-cell malignancies was indeed the first identified tumor-
specific antigen able to elicit a T-cell response (19, 20). The crucial 
interactions between lymphoma cells and the immune microen-
vironment for their maintenance and progression, in particular 
in the case of HL and indolent B-NHLs (21), have underscored 
other potential immunotherapeutic targets. Tumor-infiltrating 
immune cells, including T lymphocytes, macrophages and DCs, 
can provide survival signals for malignant B cells (22, 23). As an 
example, FL growth strictly depends on stromal cells, such as fol-
licular DCs, which provide anti-apoptotic signals through CD40 
(24, 25). On the other hand, T regulatory cells (Tregs) (26–28) 
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and immunosuppressive lymphoma-associated macrophages 
(29–31) can contribute to lymphoma growth by dampening the 
immune system attack. Therefore, acting on the immune micro-
environment can also be exploited as a rational anti-lymphoma 
immunotherapeutic treatment.
The following sections review the most important and recent 
advances in anti-lymphoma immunotherapy, with a particular 
focus on strategies exploiting the T-cell arm of the immune 
response against B-NHLs.
Anti-Lymphoma immunotherapy
Anticancer immunotherapy is aimed at eradicating tumor cells 
by conferring either a passive or an active specific immunity 
with less toxic effects than using conventional anticancer agents. 
Passive immunotherapy is meant to supply the immune response 
through the infusion of tumor-specific mAbs or cytotoxic T cells 
TABLe 1 | B-cell lymphoma classification.
Lymphoma Frequency 
among 
lymphoma (%)
Proposed cellular 
origin
Chromosome 
translocation 
(frequency)
Tumor-suppressor 
gene mutation 
(frequency)
viruses 
(frequency)
Other alterations 
(frequency)
cHL 9 GC B cells – SOCS1 (40), NFKBIA 
and NFKBIE (10–20), 
A20 (40)
EBV (40) Mutation of multiple 
oncogenes, including REL 
(30), JAK2 (20), NIK (25)
NLPHL 1 GC B cells – EBV
B-CLL 7 CD5+ small memory, 
naive, or marginal-
zone B cells
– ATM (30), TP53 (15) – Deletion on 13q14 (60)
MCL 5 CD5+ mantle-zone 
B cells
CCND1-IgH (95) ATM (40) – Deletion on 13q14 (50–70)
FL 20 GC B cells BCL2-IgH (90) – – –
MALT 7 Marginal-zone B cells API2-MALT1 (30), 
BCL10-IgH (5), MALT1-
IgH (15–20), FOXP1-IgH 
(10) 
CD95 (5–80) Indirect role of 
Helicobacter Pylori 
in gastric MALT 
lymphomas
–
MZL 2 Marginal-zone or 
monocytoid B cells
– – – –
Splenic MZL 1 Small IgD+ naive 
marginal-zone B cells
– – – Deletion on 7q22–36 (40)
BL 2 GC B cells MYC-IgH or MYC-IgL 
(100)
TP53 (40), RB (20–80) EBV (endemic, 95; 
sporadic, 30)
–
DLBCL 30–40 Post-GC B cells BCL6–various (35) BCL2-
IgH (15–30) MYC-IgH or 
MYC-IgL (15)
CD95 (10–20), ATM 
(15), TP53 (25)
– Aberrant hypermutation of 
multiple proto-oncogenes 
(50)
Primary mediastinal 
B-cell lymphoma
2 Thymic B cells – SOCS1 (40) – Mutation of multiple  
proto-oncogenes (40)
Post-transplant 
lymphoma 
<1 GC B cells – – EBV (90) –
Primary effusion 
lymphoma
<0.5 (Post) GC B cells – – HHV8 (95), EBV 
(70)
–
LPL; Waldenstrom’s 
disease
1 (Post) GC B cells PAX5-IgH (50) – – –
cHL, classical Hodgkin’s lymphoma; NLPHL, nodular lymphocyte predominant Hodgkin’s lymphoma; B-CLL, B-cell chronic lymphocytic leukemia; MCL, mantle-cell lymphoma; 
FL, follicular lymphoma; MALT, mucosa associated lymphatic tissue lymphoma; MZL, marginal zone lymphoma; BL, Burkitt’s lymphoma; DLBCL, diffuse large B-cell lymphoma; 
LPL, lymphoplasmacytic lymphoma; GC, germinal center.
(CTLs), with the major limitation that it may be short-lived. 
Active immunotherapy instead is thought to stimulate an endog-
enous immune response to clear neoplastic cells and induce a 
specific immunological memory that controls disease recurrence, 
and thus represents an ideal immunotherapeutic modality. More 
recently, thanks to the development of immunomodulatory 
agents, a new area of immunotherapy has started to be explored 
with the aim to induce and/or sustain endogenous antitumor 
immune responses, providing substantial clinical results.
B-NHLs, in particular the indolent forms, represent one of 
the most suitable settings for immunotherapeutic interven-
tions. They have long been regarded as highly immune sensitive 
diseases, based on the detection of lymphoma-specific CTLs in 
B-NHL patients (32) and reports of spontaneous regressions in 
10–20% of the low-grade cases. Moreover, the course of indolent 
lymphomas leaves an optimal therapeutic window to study 
immunotherapy without affecting the standard of care of these 
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patients, given that immunotherapy, relying on endogenous 
immune system functions, may require longer periods of time to 
induce a therapeutic effect.
In the last two decades, a number of immune-based treat-
ments have been developed and tested in B-NHL patients. To 
date, the use of mAbs directed against B-NHL antigens has 
produced the most convincing results, with rituximab being the 
prototype example in this treatment category. The introduction 
of rituximab-based chemoimmunotherapy has improved the 
overall survival (OS) of indolent lymphoma patients, providing a 
change in the natural history of these diseases (33, 34). However, 
resistance to rituximab remains a problem (35) and more effective 
regimens are still needed. MAbs for new lymphoma targets as 
well as new generation Abs are thus being developed with the aim 
to further ameliorate patients’ outcome.
Patient-specific vaccines targeting the clonally derived Ig-Id 
protein or the whole antigenic tumor repertoires have been 
largely tested against B-NHLs, with certain degrees of success also 
in severely pretreated patients (36). Furthermore, on the basis of 
the high sensitivity of these diseases to graft-versus-tumor effects 
after allogeneic bone marrow transplantation/donor lymphocytes 
infusions (DLIs), adoptive transfer of tumor-specific CTLs has 
been also used in lymphoma patients (37, 38). Building upon these 
findings, lymphoma-specific chimeric antigen receptor (CAR)-
engineered T cells are now being explored for the treatment of 
lymphoma patients with very promising results (39). Finally, the 
availability of immune checkpoint-blocking agents (40, 41) now 
allows the opportunity to counteract immune tolerant mecha-
nisms, which are considered the major obstacle to the efficacy 
of anticancer immunotherapy, and to explore potentially more 
effective immunotherapeutic combinations against B-NHLs.
Active immunotherapy for B-Cell 
Lymphomas
The availability of a tumor-specific antigen in B-NHLs enabled 
the development of specific vaccines. Id immunodominant pep-
tides or the whole Id determinants have been extensively used to 
vaccinate patients as protein- or DNA-based vaccines or loaded 
into DCs (Figure 1) (36). Different types of carriers and immune 
adjuvants have been combined with these vaccines to potentiate 
the activation of an immune response against a self-antigen. As 
an alternative strategy to reduce the complexity of the produc-
tion of patient-specific Id and widen the spectrum of targeted 
tumor-associated antigens (TAAs), vaccines based on the whole 
lymphoma proteome have been investigated. Whereas protein- 
and DNA-based vaccines are designed to target DCs in  vivo, 
whole tumor cell antigens have been usually loaded into DCs 
ex vivo, with the advantage to select/generate the most suitable 
source of DCs able to efficiently present TAAs and activate an 
immune response in vivo upon injection (Figure 1).
Protein-Based vaccines
Anti-Id vaccines have used Id proteins produced by either somatic 
hybridization of tumor cells with a myeloma cell line (hybridoma), 
or recombinant technology, by cloning Ig genes into stable cell 
lines (36). The latter strategy is faster, taking 1 month, but in con-
trast to the hybridoma technology, the Id glycosylation pattern, 
and in turn immunogenicity, is strictly dependent on the origin of 
the cell line used (42). The capability of the Id vaccination to induce 
tumor protection was extensively demonstrated in plasmacytoma, 
myeloma, B-cell lymphoma, and leukemia preclinical models 
(36). Being per se a weakly immunogenic protein, the Id was con-
jugated to the carrier protein keyhole limpet hemocyanin (KLH) 
and co-administrated with low-dose granulocyte-macrophage 
colony-stimulating factor (GM-CSF). This strategy demonstrated 
to promote anti-Id B- and T-cell responses associated with thera-
peutic effects in animals with low tumor burden (36), and paved 
the way for the clinical evaluation of anti-Id vaccination.
Early-phase clinical studies were performed in indolent B-NHL 
patients in clinical remission after standard chemotherapy regi-
mens, using Id proteins produced either by hybridoma or recom-
binant technology, conjugated with KLH and co-administered 
with low-dose GM-CFS or Syntex adjuvant formulation (43). 
These studies demonstrated the feasibility of producing patient-
specific Id-vaccines, and the safety and efficacy of this strategy 
to induce anti-lymphoma immune responses, eventually associ-
ated with an improved clinical outcome (43). In line with the 
preclinical results, the co-administration of low-dose GM-CSF 
with Id-KLH showed to promote anti-Id T-cell responses and 
molecular remissions in patients with minimal residual disease 
after prednisone, doxorubicin, cyclophosphamide, and etoposide 
(PACE) induction therapy (44). In a following trial, anti-Id vac-
cination after cyclophosphamide, doxorubicin, vincristine, pred-
nisone (CHOP)-like second-line induction therapy resulted in 
longer clinical remissions compared to those achieved in the same 
patients by the front-line standard therapy (45). Interestingly, 
patients mounting either an Ab or a T-cell anti-Id response after 
vaccination experienced the longest second complete remission, 
providing the first in-human evidence of the association between 
vaccine-specific immune responses and clinical efficacy. A 
more recent retrospective study demonstrated that achieving a 
complete response/complete response unconfirmed (CR/CRu) 
to induction chemotherapy and developing anti-Id Abs were 
two independent factors that each correlated with longer OS at 
10 years after vaccination (46). This study included FL patients who 
received vaccines produced by either the hybridoma or recombi-
nant technology in both mammalian cells and in tobacco plants. 
Interestingly, the probability of developing an anti-Id immunity 
was not influenced by the method of vaccine generation, although 
in patients vaccinated with hybridoma-derived Id, the rate of 
specific T-cell responses trended to be higher and the correla-
tion between anti-Id Ab responses and OS resulted particularly 
significant (46). This is probably due to the presence of a more 
physiological glycosylation pattern in the hybridoma-derived 
Id, which may improve the immunogenicity of the Id. Given the 
critical role of the induction of anti-Id immune responses for 
the therapeutic efficacy of Id vaccination, two clinical trials with 
Id-KLH + GM-CSF explored the impact of B-cell depletion by 
rituximab as part of the induction therapy before vaccination. 
Importantly, they showed that, even if delayed, Id-specific Ab 
responses could be equally achieved, whereas the induction of 
antitumor T-cell immunity was not affected (47, 48). Remarkably, 
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an improved time to progression (TTP) was reported for patients 
receiving vaccination after rituximab compared to the historical 
controls treated with rituximab alone, suggesting a potential 
clinical benefit of active immunotherapy also in the setting of 
B-cell recovery after rituximab therapy.
The feasibility, tolerability, and efficacy of Id vaccines demon-
strated in early-stage clinical trials led to the initiation of three 
large-scale randomized phase-III studies aimed at demonstrating 
a clear-cut survival improvement in vaccinated patients. They 
tested either recombinant Id (MyVax, Genitope Corporation (49); 
FavId, Favrille) (50) or hybridoma-derived Id (BiovaxId, Biovest 
International Inc.) (51) in grades 1–3 FL patients that achieved 
at least disease stabilization (50), partial (49) or complete (51) 
remission after induction with a standard course of rituximab or 
cyclophosphamide, vincristine and prednisone (CVP) or PACE, 
respectively (Table 2).
The Genitope trial enrolled 287 previously untreated patients 
with the aim to show a significant increase in disease-free survival 
(DFS) in the vaccinated cohort as its principal endpoint. Even 
though this was not achieved, among the vaccinated patients, 
those who mounted an anti-Id immune response experienced 
a significantly improved PFS, further strengthening the correla-
tion between the induction of vaccine-specific immune effects 
and the clinical benefit (49). The Favrille study compared TTP 
between the vaccine and control cohorts, who included 349 
patients in total, with ~80% being treatment-naïve, but failed to 
FiGURe 1 | immunotherapeutic strategies under investigation against 
B-cell lymphomas. Several approaches have been developed to induce 
therapeutic anti-lymphoma T-cell responses, by either targeting dendritic cells 
(DCs) in vivo or ex vivo, or adoptive transfer of specific cytotoxic T cells (CTLs), 
and/or appropriate modulation of T-cell functions in vivo. Active immunization 
with patient-specific Id proteins or DNA plasmids encoding for the Id have 
been exploited to target DCs in vivo and activate T cell against B-cell 
lymphomas. DCs optimally pulsed ex vivo with lymphoma antigens (Id or 
whole tumor antigens) have been employed as vaccines to improve the 
stimulation of specific T cells in vivo. To bypass in vitro manipulation, the 
strategy to induce in vivo immunogenic lymphoma cell death (with radiation 
therapy) and activation of DCs (with the TLR agonist CpG) has been studied to 
favor the occurrence of a vaccinal effect in vivo (in situ vaccination). To 
overcome the difficulties of generating endogenous T-cell responses able to 
eradicate tumors in pluritreated lymphoma patients, adoptive transfer of 
activated tumor-specific T cells (such as anti-lymphoma CAR-engineered 
T cells) has been also investigated. Finally, the availability of several 
immunomodulatory agents offers the opportunity to target the tumor immune 
microenvironment from multiple sides. Blocking Abs against the immune 
checkpoints PD-1 and CTLA-4 are among the first therapies in the pipeline to 
be tested with the aim to boost T-cell functions and counteract 
immunosuppression in lymphoma patients.
demonstrate any clinical improvement in the experimental arm 
(50). Unfortunately, immune responses were not monitored in 
these patients and the association between immunological and 
clinical effects could not be verified. The Biovest trial enrolled 
234 previously untreated patients: 177 achieved a CR/CRu after 
induction chemotherapy and were thus randomized, but 60 of 
these patients did not receive the vaccine because of relapse 
or other reasons, thus missing the expected intention to treat 
(ITT) endpoint. However, among the treated patients, those who 
received the vaccine (n = 76) experienced a prolongation of the 
DFS by 13.6 months compared to those treated with the placebo 
(n = 41) (44.2 versus 30.6, p = 0.045), but without any increase 
in OS (51). In particular, treatment with Id of the IgM class, but 
not IgG, showed to significantly improve DFS compared to the 
isotype-matched control (52.9 versus 28.7  months; p =  0.001). 
Although results from the Biovest study are not definitive because 
of the non-met ITT and the low statistical significance level of 
the difference in DFS between the two cohorts, they granted 
BiovaxId the orphan drug status by the FDA. For a proper inter-
pretation of this study, it is important to consider that patients 
who received the vaccine had to remain in remission during 
the period of the vaccine preparation. Since the average time of 
vaccine production was 8 months, it is possible that vaccinated 
patients had less aggressive and/or less chemoresistant diseases, 
thus explaining a longer-lasting complete response. Alternatively, 
these results may simply reflect the concept that complete tumor 
TABLe 2 | Main features and interpretation of phase-iii clinical trials with anti-id vaccination.
  Genitope Favrille NCi/Biovest
Vaccine MyVax FavId BiovaxId
Patients FL, untreated FL, 80% untreated FL, untreated
Source of tumor FNA/core biopsy FNA/core biopsy Excisional biopsy
Idiotype Recombinant Recombinant Hybridoma
Induction therapy CVP (8 cycles every 3 weeks) Rituximab (weekly ×4) PACE/R-CHOP (6–8 cycles every 
4 weeks)
Type of comparison  
(experimental/control)
2/1 randomization 1/1 randomization 2/1 randomization
Patient status before vaccination First CR or PR First CR, PR, or SD First CR or CRu
Vaccination Id-KLH + GM-CFSE or KLH + GM-CSF 
(sc, 7 doses)
Id-KLH + GM-CFSE or 
placebo + GM-CSF (sc, until PD)
Id-KLH + GM-CFSE or KLH + GM-CSF 
(sc, 5 doses)
Number of patients (actual/
expected)
Vaccine: 192/240; control: 95/120 Vaccine: 174/171; control: 175/171 Vaccine: 76/250; control: 41/125
Primary end point PFS (p < 0.01) TTP (p < 0.01) DFS (p < 0.01)
Results Median PFS, 19.1 (experimental) versus 
23.3 (control) mos (p = 0.297)
Median TTP, 9 (experimental) versus  
12.6 (control) mos (p = 0.019)
Median DFS, 44.2 (experimental) versus 
30.6 (control) mos (p = 0.045)
Reference (49) (50) (51)
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CNOP, cyclophosphamide, mitoxantrone, vincristine, and prednisone; RTX, Rituximab; CRu, complete response 
unconfirmed; CVP, cyclophosphamide, vincristine, and prednisone; DFS, disease-free survival; GM-CSF, granulocyte-macrophage colony-stimulating factor; ITT, intent to treat; KLH, 
keyhole limpet hemocyanin; n.s, not significant; PACE, prednisone, doxorubicin, cyclophosphamide, and etoposide; PFS, progression-free survival; pts, patients; CR, complete 
response; PR, partial response; SD, stable disease; TTP, time to progression; mos, months.
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eradication predisposes to the achievement of a clinical benefit 
after vaccination.
Although the outcome of these phase-III clinical studies did 
not meet the high expectation, they have provided important 
information to improve the design of future trials. They indeed 
confirmed in significantly larger cohorts of patients (1) the safety 
and tolerability of Id-KLH produced either by recombinant or 
hybridoma technology; (2) the potential advantage of the latter 
method for the generation of more immunogenic and effective 
Id vaccines; and (3) the importance of inducing complete remis-
sion before vaccination in order to increase the probability of 
a clinical success. Moreover, results from these studies point to 
patients’ selection and vaccine formulation as the areas with the 
highest room for potential improvement, in particular in view 
of the better definition of the molecular prerequisites to achieve 
an effective antitumor immune response. Importantly, these 
findings may be useful to optimize the design of anti-lymphoma 
active immunotherapy across different types of vaccines.
DNA-Based vaccines
As an additional option to target DC in vivo and immunize cancer 
patients, viral vectors and plasmid DNA encoding TAAs have been 
exploited. This strategy requires in vivo transfection and antigen 
production. The optimized gene sequence is delivered intrader-
mally, subcutaneously, or to the muscle, which allows, respectively, 
the in vivo transfection of professional APCs (epidermal keratino-
cytes and Langherans DCs) or myocytes and secondary cross-pres-
entation of tumor antigens by the recruited DCs. The advantages of 
DNA-based vaccines over other immunization strategies include 
(1) the possibility of incorporating multiple epitope-encoding 
DNA regions to target several antigens in a single vaccine formula-
tion, (2) no need to know the human leukocyte antigen (HLA) type 
because the protein products are processed in vivo by host APCs, 
(3) low production costs, and (4) the easy procedure required 
for their generation. However, as a drawback, it is possible that 
antigen expression, processing, and presentation take place in the 
improper cell subsets without the adequate stimuli, thus resulting 
in tolerance or an unwanted type of immunity rather than in the 
priming of an antitumor adaptive immune response (52).
Initial clinical trials demonstrated the feasibility and safety of 
vaccination with Id-encoding plasmid DNA, with no relevant lev-
els of integration into host cellular DNA, or development of auto-
immune reactions. However, due to the limited biological efficacy 
and no clinical benefit of Id-encoding naked DNA plasmid (53), 
more potent Id-DNA vaccines were generated by fusing the Id 
sequence to virus-derived immune stimulatory sequences (such 
as the fragment C of the tetanus toxin) (54) or cytokine-encoding 
genes (55), to favor DC chemotaxis, antigen uptake and presenta-
tion. In in  vivo lymphoma models, these formulations showed 
prophylactic and therapeutic antitumor effects that relied on the 
induction of a specific T-cell response. As an additional strategy, 
pretreatment of the vaccination sites with low-dose cardiotoxin 
was found to generate a favorable immune microenvironment, 
which facilitated antigen-specific T-cell priming toward a long-
term antitumor immunological memory (43).
The availability of more and more accurate mathematical 
algorithms for a better prediction of the most immunogenic 
peptides within TAAs will probably favor improving the design 
of DNA-based vaccines in the near future (56).
September 2015 | Volume 6 | Article 4487
Zappasodi et al. Lymphoma immunotherapy
Frontiers in Immunology | www.frontiersin.org
DC-Based vaccines
To overcome the limitation of producing a custom-made protein 
for each patient, targeting a single antigen, and relying on the 
host’s antigen processing machinery, presentation, and T-cell co-
stimulation, loading DCs ex vivo with TAAs in the presence of the 
proper activation stimuli has also been exploited. In this case, DCs 
are properly differentiated from CD34+ hematopoietic progenitors 
or, more commonly, from peripheral blood monocytes in the pres-
ence of the proper DC differentiation and maturation cytokine 
cocktails, and pulsed with TAAs as to recapitulate ex vivo the early 
phase of DC activation. The source of DCs, TAAs, the antigen-
engulfing strategy, cytokine cocktails, and the route of vaccine 
administration can be multiple and require precise consideration 
to optimize the therapeutic efficacy of DC-based vaccines (52).
Clinical efficacy of DC-based vaccines seems to be superior 
compared to that achieved by Id-protein vaccines against lym-
phoma (57), confirming observations in different tumor settings 
of the advantages of this strategy over protein-based vaccines 
(58). Interestingly, when a DC-vaccine was used to immunize 
against the single antigenic Id protein, FL patients with relapsed or 
residual diseases after induction therapy developed anti-Id T-cell 
and Ab responses associated with durable tumor regressions, in 
particular when Id was conjugated with KLH (59). DCs loaded 
with tumor cell lysates showed to elicit significant anti-lymphoma 
immunity in preclinical models (60) and in small clinical trials 
(61). In a pilot study, we showed that vaccination with autolo-
gous DCs loaded with apoptotic and necrotic autologous tumor 
cells increased natural killer (NK) cell activation, reduced Treg 
frequency and induced both T- and B-cell antitumor responses 
associated with clinical efficacy in 6 of 18 heavily pretreated indo-
lent B-NHL patients with measurable disease (61). Interestingly, 
in responder patients, the humoral responses induced by vaccina-
tion were directed against common lymphoma antigens (62). Of 
note, we showed that the levels of immunogenic stimuli in dying 
lymphoma cells used to pulse DCs positively correlated with the 
probability of a clinical success of the vaccine (63). Therefore, 
favoring the occurrence of this process, namely immunogenic cell 
death (64), by exogenously supplying antigenic/proinflammatory 
signals to boost DC engulfing, cross-presentation, and matura-
tion, may increase the efficacy of DC-based vaccines.
As additional modalities to load DCs ex vivo with the full 
lymphoma antigenic repertoire, fusion of DCs with tumor cells 
(65) and transduction of DCs with tumor-derived mRNA have 
started to be investigated in the preclinical setting (66–68). The 
latter is a promising technique in light of the minimal sample 
size required for the amplification of total tumor RNA, which 
considerably decreases the cost of vaccine production. However, 
it has to be considered that DC transduction channels TAAs 
primarily into the MHC-I presentation pathway, thus limiting the 
activation CD4+ T cells (69), which are crucial to sustain both Ab 
and CTL responses.
In Situ vaccination
The understanding that certain anticancer treatments, includ-
ing antracyclines and radiation, can favor the induction of an 
immunogenic tumor cell death (64), supported the possibility to 
combine them with proper immune adjuvants to achieve in vivo 
a vaccinal antitumor effect (Figure 1). To facilitate in vivo TAA 
processing and T-cell cross-priming, toll-like receptor (TLR) 
agonists are particularly suitable as they can activate and bridge 
the innate and adaptive immunity (70). The preclinical observa-
tion that intratumoral injection of the TLR9 agonist CpG oligo-
deoxynucleotides plus systemic chemotherapy eradicated large 
tumors inspired the clinical evaluation of low-dose locoregional 
radiation plus intratumor CpG injection in low-grade B-NHL 
patients (71). This approach achieved clinical responses at distal 
tumor sites (abscopal effect) in association with the induction of 
tumor-reactive CD8+ T cells and reduction of intratumor Tregs 
(71). This study underscored the feasibility, safety, and efficacy to 
provide the conditions for the in vivo generation of an antitumor 
vaccine, thus overcoming the limitations for the manufacture 
of patient-specific products. Following these promising results, 
in  situ vaccination with GpC and local radiation therapy was 
evaluated in resistant/refractory cutaneous-T-cell-lymphoma 
patients in a phase I/II study (72). Also in this case, treatment 
resulted safe and achieved systemic clinical responses, somehow 
associated with a positive immune modulation, in one-third of 
the patients. These findings point to the availability in the near 
future of a non-customized vaccine approach widely applicable 
with no requirement of any ex vivo cellular manipulation.
As a complementary modality to in situ vaccination, adoptive 
transfer of vaccine-primed autologous T cells after in vitro expan-
sion, namely immunotransplant, has been exploited. Upon the 
achievement of the proof-of-concept in preclinical models (73), 
patients with newly diagnosed MCL were subjected to this pro-
cedure. In this case, the vaccine was made of autologous tumor 
cells that were treated in  vitro with CpG and irradiated before 
administration into patients previously exposed to cytoreduc-
tive standard chemotherapy (74). Vaccine-primed T cells were 
then harvested, expanded in vitro, and reinfused after standard 
autologous stem cell transplantation. Preliminary results showed 
the feasibility of this approach in aggressive lymphoma patients 
and its efficacy in boosting antitumor T-cell responses. This 
provides the proof-of-principle for further investigations of the 
sequential combination of active and adoptive immunotherapy 
in cancer patients.
T-Cell Therapies
The ultimate objective of active immunotherapy is to induce an 
endogenous immune response able to activate T cells against the 
tumor. The clinical experience with anti-lymphoma vaccines has 
clearly shown a limited efficacy of this strategy to consistently 
expand a sufficient number of activated antitumor T cells able to 
clear established tumors in pluritreated patients. With the same 
rationale of the use of immunotransplant, lymphoma patients can 
be adoptively transferred with an adequate amount of tumor-spe-
cific T cells optimized ex vivo to recognize and kill cancer cells, in 
order to maximize the probability to achieve a therapeutic effect 
(Figure  1). Two main T-cell therapeutic strategies have shown 
considerable success against B-cell lymphomas: transfer of EBV-
specific T cells for the treatment of EBV-associated lymphomas 
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and CAR T cells engineered to target B-cell lineage markers that 
continue to be expressed in the malignant clones.
Post-transplant lymphoproliferative diseases (PTLDs), caused 
by the reactivation of EBV infection in B cells of donor or recipi-
ent origin after allogeneic hematopietic stem cell transplantation 
(HSCT) or solid organ transplants (SOTs) respectively, continue 
to be a significant clinical problem (75). Management of heavily 
immunosuppressed patients with anticancer treatment poses 
several limitations, and standard treatment with rituximab 
eventually associated with less-intensive chemotherapy regimens 
often fail to cure PTLDs (76). EBV-infected B-cells do not actively 
produce virus, and, as such, are not sensitive to antiviral agents 
(77), but express viral latency-associated proteins, which may 
represent effective targets for immunotherapy. Depending on the 
type of latency of EBV, malignant B cells express more or less 
immunogenic EBV antigens. Tumors that arise in severely immu-
nocompromised patients, such as in the early phases after allogenic 
HSCT or in SOT recipients, are usually highly immunogenic and 
express all the 10 EBV latency-associated proteins. Expressing the 
same 10 viral antigens and high levels of class-I and class-II HLA 
as well as co-stimulatory molecules, EBV-transformed B cells are 
optimal APCs for the activation of HLA-matched EBV-specific 
T cells to be used in this setting. With this strategy, polyclonal 
anti-EBV CTLs have been rapidly and abundantly generated from 
healthy EBV-seropositive donors, and proved safe and effective 
in preventing or treating PTLDs in recipients of allogenic HSCT 
(78, 79). Based on these encouraging results, a similar strategy 
has been attempted to treat post-SOT PTLDs. In this case, anti-
EBV CTLs have been generated from the organ recipients and 
demonstrated some success in patients with either elevated EBV 
viral load or active disease (80–82). The constant immunosup-
pression status and the fact that SOT patients do not receive any 
lymphodepleting pre-conditioning treatment, which instead 
favors T-cell expansion in HSCT recipients, may account for 
the reduced persistence and efficacy of the transferred anti-EBV 
CTLs in this setting. However, these results have been crucial to 
demonstrate the feasibility of anti-EBV T-cell therapy in SOT 
recipients and the absence of any risk to induce rejection of the 
transplanted organ.
Interestingly, efficient control of PTLD was also achieved 
when “off-the-shelf ” EBV-specific T cells derived from partially 
matched third-party donors were used in the context of both SOT 
and HSCT (79, 83, 84). This represented a dramatic improvement 
in the management of PTLD patients as anti-EBV CTLs of differ-
ent HLA specificities may be generated and banked in advance 
in order to be readily available when needed. Very recently, anti-
EBV CTLs derived from either patient’s transplant or third-party 
donors have shown similar substantial efficacy in producing 
long-lasting remissions in patients with aggressive rituximab-
resistant post-HSCT PTLDs [(85), AACR Annual Meeting 2015, 
abstract CT107]. These results granted breakthrough therapy 
designation to anti-EBV CTLs generated from third-party donors 
for the treatment of patients with rituximab-refractory PTDLs.
Since EBV-related HLs and B-NHLs express only the weakly 
immunogenic EBV latency proteins (type II EBV latency 
proteins, LMP1, LMP2, and EBNA-1) (86), T cells specific for 
these antigens rather than polyclonal anti-EBV T cells need to 
be infused in order to achieve a clinical effect. However, the time 
required for their generation makes the procedure not suitable for 
the treatment of patients with active disease (87). For the same 
reason, T-cell therapy has not been developed for the treatment 
of the type-I EBV latency BL, which express only the poorly 
immunogenic protein EBNA1.
To broaden the specificity of T cells against multiple TAAs, 
transduction of high-affinity TCRs or CARs into mature or 
precursor T cells have been accomplished to make adoptive 
immunotherapy more easily available for patients with different 
tumor types (88). This latter option has found relatively wide 
application for the treatment of B-cell malignancies. CARs 
contain an extracellular domain with the Ab variable regions 
recognizing the target TAA genetically fused to the intracellular 
CD3ζchain (89). T cells transduced with CARs are therefore redi-
rected toward the target antigen via the Ab regions, which, once 
engaged, trigger the CD3ζchain-downstream signaling cascade 
for T-cell activation. The activity of CAR-T cells thus becomes 
independent from HLA recognition, and this constitutes a major 
advantage of this strategy. The consistent expression of the B-cell 
lineage markers CD19 and CD20 across most B-cell malignancies 
and the reported safety/efficacy of anti-CD19/-CD20 mAbs in 
these diseases made them the preferred targets for CAR-T cells. In 
the preclinical setting, first generation CAR-T cells against CD19 
or CD20 (CD19-/CD20-ζ) showed adequate engraftment and 
anti-lymphoma activity in either mice xenografted with patients’ 
tumors and autologous CAR-T cells or in syngeneic murine 
models following lymphodepletion with cyclophosphamide or 
radiation (90–93). However, the limited persistence of these CAR 
T-cells, partially driven by the presence of endogenous normal B 
cells expressing the target antigens (92, 94), led to the development 
of second-generation CARs, where the CD3ζ region was fused 
to the intracellular signaling domains of T-cell co-stimulatory 
molecules, such as CD28 or CD137 (4-1BB). CD19⋅CD28-ζ and 
CD19⋅CD137-ζCAR-T cells demonstrated enhanced functions, 
proliferation and survival, and resistance to Treg suppression, 
which resulted in increased persistence and antitumor activity in 
xenografted mice (95–99). This strategy seemed to be particularly 
effective when the tumor cells expressed low levels of ligands for 
co-stimulatory molecules (95, 97), because, being transduced 
with co-stimulatory domains, second-generation CAR-T cells 
did not depend anymore on physiologic co-stimulation signals. 
Third generation CAR-T cells with all the three T-cell signaling 
domains fused together (CD3ζ, CD28, and 4-1BB) have not 
definitely proven to exert a better antitumor activity (98, 100). 
Another approach studied with the aim to increase CAR-T cell 
in vivo persistence has been to engineer T cells specific for com-
mon viruses, such as EBV. Transduced virus-specific lymphocytes 
maintain the capability to become physiologically activated in vivo 
through their natural T-cell receptor and to persist in the memory 
compartment, offering the advantage to control their expansion 
by vaccination with the cognate viral antigens (101, 102).
Based on these preclinical findings, clinical studies mainly 
investigated second-generation CARs, either with CD28 or 4-1BB 
signaling domains, alone or in combination with lymphodeplet-
ing conditioning regimens. Experience accumulated so far in 
patients with B-cell malignancies indicates (1) the feasibility of 
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generating and using CARs in the clinical setting, (2) the advan-
tage of retro/lentiviral gene transduction methods over plasmid 
transfection technology to generate more functional CAR-T cells 
(no resistance selection genes, shorter culture periods), and (3) 
the importance of lymphodepleting pre-conditioning treatments 
to facilitate engraftment and in turn the therapeutic effects of 
CAR-T cells, with no specific restriction to the regimen to be 
applied. These observations, made initially in early small clinical 
trials with refractory/resistant B-NHL and acute lymphoid leuke-
mia patients, are being confirmed in larger studies (39, 103–106). 
Persistent clinical responses and relatively manageable toxicities 
were induced by autologous CD19 CAR-T cells in patients relaps-
ing after multiple lines of treatments. Interestingly, this approach 
proved effective also when donor-derived allogeneic CAR-T cells 
were administered in B-NHL patients who relapsed or were at 
high risk to relapse after allogeneic HSCT (107). Redirecting 
allogenic T cells against a TAA with CARs appeared an effec-
tive strategy to uncouple graft-versus-host-disease (GVHD) and 
graft-versus-leukemia (GVL) effect in patients who failed HSCT 
and DLI. In this context, the use of virus-specific T cells for the 
generation of donor-derived CD19 CAR-T cells showed promis-
ing results in controlling both the disease and viremia in patients 
with viral reactivation after allogeneic HSCT (108).
Altogether these findings indicate the substantial therapeutic 
potential of CAR-T cells against B-cell malignancies; however, 
this approach has still a wide margin for improvement, which 
mainly relies on the need for a better understanding of the biol-
ogy of CAR-T cells, more robust biomarkers of clinical response 
and methods to reduce toxicity. Cytokine release syndrome and 
neurologic toxicities are not uncommon side effects of CAR-T 
cells. Therefore, there is a huge effort toward the understanding 
of how to control the functions of these T cells. Preclinical studies 
have investigated the potential to eliminate CAR-T cells in case 
of toxicity by co-transducing chemically inducible apoptosis-
promoting fusion proteins, such as Fas and Caspase 9 (109), or 
targets of cell-depleting antibodies, such as CD20 or truncated 
epidermal growth factor receptor (110, 111). By eliminating 
CAR-T cells themselves, however, such strategies abolish both 
their side effects and therapeutic potential. As an alternative 
option, already tested in patients, blocking IL-6 receptor with 
the specific mAb tocilizumab has shown promising results in 
reversing cytokine release syndrome while sparing expansion and 
therapeutic effects of CAR-T cells (112, 113).
Finally, in light of the potential ability of tumor cells to 
escape CAR-T cell therapy, for example, by downregulating the 
expression of the targeted antigen (112), it is important to study 
strategies for counteracting such mechanisms. Toward this goal, 
CAR-T cells engineered to target multiple and/or alternative 
(114, 115) lymphoma antigens or their combination with other 
immunotherapeutic modalities are under investigation.
Targeting the immune Microenvironment 
in Lymphoma
In order to grow and progress in lymphoid organs, lymphomas 
need to subvert immunosurveillance while preserving the pro-
lymphomagenic functions of nearby immune cells, thus becoming 
real parasites of the immune system. The prototype example of the 
role of the crosstalk with immune cells in the lymphoma microen-
vironment is HL, where the Hodgkin and Reed–Sternberg (HRS) 
tumor cells account only for 1% of the affected tissue, being the 
rest all inflammatory cells, which provide crucial interactions 
through CD80 and CD40/CD40L for HRS cell survival. In this 
case, mechanisms of immune evasion include polarization of 
infiltrating T cells toward a T helper 2/Treg phenotype through 
the release of IL-10 and TGF-beta, and inhibition of NK cells 
and CTLs via overexpression of FAS ligand and the ligands of 
the immune checkpoint receptor programed-death 1 (PD-1) 
(116). As an additional demonstration of the importance of the 
immune infiltrate in lymphoma development and progression, 
genetic and immunohistochemical signatures of non-tumor cells 
in the neoplastic tissue currently represent the best predictors for 
B-NHL patients’ prognosis (29, 117–120). These studies showed 
that a reduced survival and the risk of transformation of indolent 
B-NHLs are associated with the infiltration of specific immune cell 
subsets. In particular, lymphoma-associated macrophages (29), 
CD4+CD25+FOXP3+ Tregs (121) monocytic myeloid-derived 
suppressor cells (bearing a CD14+HLA-DRlow/− phenotype) (122, 
123), and exhausted T cells expressing intermediate levels of PD-1 
(124) have been all associated with a negative clinical impact in 
FL patients. The fact that immune cells are not usually targeted 
by conventional treatments may explain why, despite major 
therapeutic advances, indolent B-NHLs still remain incurable, 
underscoring the importance of modulating the microenviron-
ment as a part of the lymphoma treatment.
Lately, several strategies able to modulate T-cell functions have 
become available, allowing preclinical and in some cases clini-
cal evaluation of the anti-lymphoma effects of Tregs inhibition, 
promotion of T-cell co-stimulation, and inhibition of immune 
checkpoints. The IL-2-diptheria toxin fusion protein denileukin 
diftitox (ontak), the anti-CD25 mAb daclizumab, and anti-folate 
receptor 4 (FR4) mAbs have been studied to deplete Tregs. Agonist 
mAbs directed against the co-stimulatory molecules, OX40 
(CD134), glucocorticoid-induced TNF-related protein (GITR), 
and 4-1BB (CD137), have been used to boost antitumor T-cell 
functions, whereas blocking mAbs for the co-inhibitory mol-
ecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) 
and PD-1 have been employed to prevent a negative regulation of 
tumor-specific T cells (Figure 1). In lymphoma preclinical mod-
els, T-cell modulation by anti-OX40, -GITR, -CD137, -CTLA-4, 
or -FR4 mAbs has shown to significantly improve the therapeutic 
efficacy of several immunotherapeutic modalities, including anti-
tumor vaccination and mAb therapy (125–127). This evidence 
has led to the clinical evaluation of T-cell modulating agents for 
the treatment of these diseases. CTLA-4 or PD-1 blockade with 
the mAbs ipilimumab or pidilizumab, respectively resulted in 
safe and induced modest but occasionally long-lasting clinical 
responses in replapsed/refractory B-NHL patients evaluated 
in early-phase trials (128–130). Interestingly the combination 
of pidilizumab and rituximab was well tolerated and active in 
patients with rituximab-sensitive FL relapsed after 1–4 previous 
therapies (131), underscoring the importance of further inves-
tigating this strategy in B-NHL patients. An unexpected thera-
peutic activity of single-agent anti-PD-1 mAb nivolumab was 
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instead found in heavily pretreated HL patients (40), which may 
thus provide a real therapeutic option for this patient category 
with an otherwise very unfavorable prognosis. The basis for the 
substantial clinical effects observed in this study probably relies 
on the high frequency of copy-number gain in PD-1 ligand loci 
in the enrolled patients (40). This points to a genetically defined 
sensitivity to PD-1 blockade in this disease. Given that genetic 
alterations of PD-1 ligands were not reported to be as frequent 
in newly diagnosed HL patients, it is possible that they define a 
subset of HLs with a particularly adverse prognosis.
Another straightforward way to redirect immune cells against 
lymphoma clones within the tumor microenvironment has been 
to modulate NK cell activity to enhance the effector functions of 
mAb therapy. As one of the major mechanisms of action of thera-
peutic mAbs is Ab-dependent cell mediated cytotoxicity (ADCC), 
whereby NK cells and phagocytes are redirected to the targeted 
tumor cells through Ab Fc receptors, the possibility to further 
co-stimulate ADCC cellular mediators via immunomodulatory 
mAbs was hypothesized to synergize with antitumor mAbs. Since 
the co-stimulatory molecule 4-1BB is upregulated on NK cells 
upon Fc receptor engagement (132), agonist anti-4-1BB mAbs 
have been investigated in combination with anti-lymphoma 
mAbs with the aim to increase antitumor ADCC. According to 
this hypothesis, agonist anti-4-1BB mAbs significantly improved 
the anti-lymphoma effects of anti-CD20 mAbs in preclinical 
models (127). In addition, human NK cells were found to con-
sistently up-regulate 4-1BB when exposed to rituximab-coated 
autologous lymphoma cells (127), providing the rationale to 
explore the combination of anti-4-1BB and -CD20 mAbs in the 
clinical setting. Based on these findings, a phase-Ib study of the 
anti-4-1BB mAb urelumab and rituximab in relapsed/refractory 
B-NHL patients has recently started (NCT01775631).
Finally, because of their immunomodulatory properties, tha-
lidomide and its derivatives have been also exploited to target the 
microenvironment in B-NHLs. Besides their potential to directly 
interfere with tumor growth and induce apoptosis in tumor cells, 
these agents promote antitumor immunity, including mAb-
mediated ADCC, and antiangiogenic effects. Lenalidomide has 
been the most widely investigated drug in this category, showing 
significant single-agent anti-lymphoma activity in phase-II trials 
(133–136), in particular against aggressive B-NHLs. Building 
upon these results, a larger phase-II study was initiated to test 
safety and efficacy of lenalidomide in MCL patients relapsed after 
a second-line therapy with bortezomib, for whom no therapeutic 
options were available (137). Based on the tolerability and durable 
clinical responses induced by lenalidomide in this patient popula-
tion, in June 2013, the FDA approved this drug for the treatment 
of MCL patients relapsed or progressed after two prior therapies 
including bortezomib. Lenalidomide has also been explored in 
combination with rituximab in relapsed/refractory indolent and 
aggressive B-NHLs showing significant and consistent clinical 
efficacy across different phase-II trials (138, 139). Interestingly, 
this combination compared favorably with single-agent rituximab 
in historical controls (5, 140). In light of the activity of lenalido-
mide against aggressive B-NHL, its combination with rituximab-
based chemotherapy (CHOP, cyclophosphamide, doxorubicin, 
vincristine, and prednisone) has been investigated as front-line 
therapy for these diseases in phase-II studies, proving to be highly 
effective and safe also in this contest (141–143). A phase-III 
randomized, double blind, placebo-controlled, and multicenter 
study to compare the efficacy and safety of lenalidomide with 
R-CHOP versus placebo with R-CHOP in patients with previ-
ously untreated DLBCL is underway (NCT02285062).
Conclusion
New curative treatments are needed for B-cell lymphomas. 
The availability of specific antigens and the easy accessibility 
of the  immune system to these diseases have supported the 
extensive study of immunotherapy in the attempt of improving 
the management of B-cell lymphoma patients. Even though active 
immunotherapy through antitumor vaccination theoretically 
represents the ideal immunotherapeutic modality to induce anti-
tumor immunity and control disease recurrences, the possibility 
to activate effective endogenous immune responses has proven 
challenging even in lymphoma patients. Alternative approaches 
to promote tumor targeting by T cells have more recently been 
investigated with promising results, with T-cell therapy regain-
ing considerable attention thanks to the recent clinical successes 
of CAR-T cells. However, with the increasing use of anticancer 
immunotherapy, we are becoming aware of the advantages and 
limitations of the different strategies now available to activate/
modulate antitumor immunity. It seems clear that if active and 
adoptive immunotherapy as well as immunomodulatory mAbs 
may not reach the desired activity as single agents, they can be 
exploited in rational combinations to maximize the probability 
of a clinical benefit (57). In conclusion, the significant advance-
ments in the development and application of immunotherapy 
against B-cell lymphomas hold promise for a better definition of 
curative options for these diseases in the near future.
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